Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II Study of Biweekly Carboplatin, Gemcitabine, and Bevacizumab as First-line Treatment in Patients with Stage IIIB/IV NSCLC

Published:2014-04 Issue:2 Volume:37 Page:140-143
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Dudek Arkadiusz Z.,Kumar Priya,H. Thaw Sunn Sunn,Cao Qing,Pawloski Pamala,Larson Timothy

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference2 articles.

1. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.;Pennell;Oncologist,2009

2. Non-parametric inference for cumulative incidence functions in competing risks studies.;Lin;Stat Med,1997

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC;Journal of Thoracic Oncology;2021-12

2. Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy;Process Biochemistry;2021-05

3. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents;Cancer;2015-11-30

4. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials;International Journal of Cancer;2014-12-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP